TCI Wealth Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

TCI Wealth Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-142	Closed	-$4.17K	–	301
2023 Q1	$4.17K	Buy	+142	New	+$4.93K	﹤0.01%	1651
2022 Q3	–	Sell	-21	Closed	–	–	2237
2022 Q2	$0	Buy	+21	New	+$249	﹤0.01%	2261

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TCI Wealth Advisors's AMLX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2023, closing a stake of 142 shares — an estimated $4.17K sold.

TCI Wealth Advisors first reported a position in AMLX in Q2 2022 and held it in 2 quarters. The position peaked at $4.17K in Q1 2023. 154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

TCI Wealth Advisors reported no remaining Amylyx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 142 Amylyx Pharmaceuticals shares in Q2 2023, an estimated $4.17K.
TCI Wealth Advisors first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 2 quarters.
TCI Wealth Advisors's Amylyx Pharmaceuticals position peaked at $4.17K in Q1 2023.
154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.